Goldman Sachs analysts removed Zealand Pharma (ZLDPF) from the firm’s European Conviction List as part of its monthly update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma initiated with a Market Perform at William Blair
- Zealand Pharma price target lowered to DKK 1,050 from DKK 1,080 at Berenberg
- Zealand Pharma’s Earnings Call: Clinical Gains and Challenges
- Zealand Pharma price target lowered to DKK 750 from DKK 755 at Morgan Stanley
- Zealand Pharma Reports Transformative Year with Strong R&D Focus